Dr Chernew leads the conversation to biomarkers in bone turnover and immunoglobulin expression.
Dr Chernew leads the conversation to biomarkers in bone turnover and immunoglobulin expression. Dr Kumar says the use of biomarkers can be very specific to a disease type. He analyzes the use of bone marrow and bone biomarkers for monitoring myeloma bone disease. He says there are both prognostic and predictive biomarkers which suit different purposes. There are also other emerging biomarkers that are being studied and explored.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More